Targeting the pathobiology of neutrophil extracellular traps

Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human inflammatory diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.

Scientific Approach

Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.

CIT-013 Development

A first human study started in the summer of 2021 starting with a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody drug product was carried out by Citryll’s CMC partner Lonza and CTA enabling studies were finalised in Spring 2021.

Jobs at Citryll

(Associate) Director Operations

The (Associate) Director Operations will provide cross-functional support for the operation of key business functions. The (Associate) Director Operations is expected to work closely with the COO and key disciplines within the organization (e.g. financial, clinical, research, business development, Quality Management System).
Read More

Latest News

Citryll announces the appointment of Maarten Kraan as Chief Medical Officer

Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
Read More

Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO 

Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.
Read More

Latest News

Citryll announces the appointment of Maarten Kraan as Chief Medical Officer

Dr. Kraan is a rheumatologist who brings more than 25 years of biopharmaceutical development experience. Dr. Kraan joins Citryll after his CMO role at AM-Pharma. Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
Read More

Citryll announces appointments of Eduardo Bravo as CEO and Tim Schenk as CBO 

Mr. Bravo has held multiple CEO positions, including in the autoimmune space, and served as Chair on various Boards.
Read More

Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
Read More